We’re committed to improving global health through the medicines we make and by advancing the global body of scientific knowledge. We also improve global health through a number of programs and partnerships that are working to improve access to medicines, strengthen healthcare systems and help people in need.
We seek to address some of the world’s most pressing global health problems through our two signature global health programs. The Lilly NCD Partnership is our response to the rising burden of non-communicable diseases (NCDs) in economically developing countries. Through this partnership, we are working to find new solutions to diabetes care for people living in impoverished communities. The Lilly MDR-TB Partnership is focused on hard-to-treat tuberculosis, or multidrug-resistant tuberculosis (MDR-TB), which disproportionately afflicts people living in poverty.
In addition, we offer a number of programs that help patients and their families as they cope with disease, sickness and the healing process. This includes a broad number of programs, such as Lilly Cares, which helps people living in the U.S. who cannot afford or don’t have access to Lilly medicines, and the Lilly Oncology on Canvas program, which helps people who have been affected by cancer express their journeys through art.
Our Elanco animal health division is focused on reducing the burden of hunger globally and in Indianapolis, where we are headquartered. Hunger is a precursor to good health, and is closely tied with Elanco’s business focus of contributing to a safe, more affordable and more abundant food supply.
We are increasingly focusing our corporate responsibility efforts on improving global health. Our goal is to be a catalyst—for ideas, solutions and action.